Tosedostat With Capecitabine in Patients With Metastatic Pancreatic Adenocarcinoma

• Sponsor: Washington University School of Medicine (Other)
• Overall Status: Terminated
• CT.gov ID: NCT02352831
• Collaborator: (none)
• Enrollment: 16
• Location: 1
• Arms: 2
• Actual Duration (Months): 37.6
• Patients Per Site Per Month: 0.4

Study Details

Study Description

Brief Summary

There are two parts to this study: the goal of the first part of the study is to find the best dose of tosedostat when given in combination with capecitabine. The goal of the second part of the study is to look at how participants respond to treatment with tosedostat and capecitabine.

Condition or Disease	Intervention/Treatment	Phase
Pancreatic Cancer; Cancer of Pancreas; Cancer of the Pancreas; Pancreas Cancer	Drug: Tosedostat; Drug: Capecitabine; Procedure: Fresh tissue biopsy	Phase 1/Phase 2

Study Design

• Study Type: Interventional
• Actual Enrollment: 16 participants
• Allocation: Non-Randomized
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Phase I/II Study Combining Tosedostat With Capecitabine in Patients With Metastatic Pancreatic Adenocarcinoma
• Actual Study Start Date: Aug 31, 2015
• Actual Primary Completion Date: Oct 20, 2017
• Actual Study Completion Date: Oct 19, 2018

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Phase I (tosedostat + capecitabine) The phase I study will be conducted in the standard 6-patient-per-cohort dose de-escalation fashion. Tosedostat by mouth daily Days 1-21 of each 21-day cycle. Dose Level 0 (starting dose) = 120 mg PO daily and Dose Level -1 = 60 mg PO daily. All 6 patients in the Phase 1 received 120 mg starting dose of tosedostat. Capecitabine 1000 mg/m^2 by mouth BID Days 1-14 of each 21-day cycle Fresh tissue biopsy: Patients who have a partial response at the end of cycle 2 will be required to undergo biopsy if deemed safe for the patient and tissue is feasible to obtain.	Drug: Tosedostat; Drug: Capecitabine; Other Names: Xeloda ; Procedure: Fresh tissue biopsy; Patients who have a partial response at the end of cycle 2 will be required to undergo biopsy if deemed safe for the patient and tissue is feasible to obtain.
Experimental: Phase II (tosedostat + capecitabine) Tosedostat (dose determined by Phase I portion of study) by mouth daily Days 1-21 of each 21-day cycle Capecitabine by mouth BID Days 1-14 of each 21-day cycle	Drug: Tosedostat; Drug: Capecitabine; Other Names: Xeloda ; Procedure: Fresh tissue biopsy; Patients who have a partial response at the end of cycle 2 will be required to undergo biopsy if deemed safe for the patient and tissue is feasible to obtain.

Outcome Measures

Primary Outcome Measures

1. Phase I Only: Recommended Phase II Dose of Tosedostat [Completion of cycle 1 of all participants in Phase I portion of study (approximately 14 months)]

   The recommended phase 2 dose (RP2D) is defined as the dose level immediately below the dose level at which 2 patients of a cohort (of 2 to 6 patients) experience dose-limiting toxicity during the first cycle. If 0 or 1 of 6 patients in Dose Level 1 experience DLT during the first cycle, Dose Level 1 will be presumed to be the RP2D. DLTs are followed through completion of the first cycle.

2. Phase I Only: Number of Participants Who Experience Dose-limiting Toxicities (DLTs) [Completion of cycle 1 of all participants in Phase I portion of study (approximately 14 months)]

   Possibly/probably/definitely related to study treatment in 1st cycle (cyc) *Grade (Gr) 4 neutropenia >7 day, Febrile neutropenia of any duration with temperature ≥ 38.5 °C, Gr 4 anemia requires transfusion therapy on more than 2 occasions in 7 days, Gr 4 thrombocytopenia Possibly/probably/definitely related gr. 3/4 non-hematologic toxicity that occurs 1st cyc with the following EXCEPTIONS: Gr 3 nausea/vomiting/diarrhea/anorexia <72 hours that returns to Gr 1 prior to the start of cyc 2, Gr 3 hand-foot syndrome will only be considered a DLT for patients who have received 1 week of supportive care treatment with no improvement, Gr 3 fatigue that returns to Gr 1 prior to the start of cyc 2, Gr 3 flu-like symptoms <72 hours that returns to Gr 1 prior to start of cyc 2, Gr 3 arthralgia or myalgias <72 hours that return to Gr 1 prior to the start of cyc 2, Gr 3 potassium/phosphorus/magnesium that is asymptomatic or of non-clinical significance <72 hours, Gr 3 hypoalbuminemia

3. Progression-free Survival (PFS) Rate [3 months]

   PFS is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first. Progressive disease (PD) Target lesions: At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progressions). Non target lesions: Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase.

Secondary Outcome Measures

1. Overall Response Rate (ORR) [Up to 18 months]

   ORR = Complete response + partial response Target lesions Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Non target lesions *Complete Response (CR): Disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (<10 mm short axis).

2. Time-to-progression (TTP) [Up to 24 months]

   -Progressive disease (PD) Target lesions: At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progressions). Non target lesions: Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase

3. Overall Survival Rate (OS) [Up to 1 year from completion of treatment (median treatment length 81.50 days (28.00-346.00)]

4. Number of Participants With a CA19-9 Response [Completion of treatment (median treatment length 81.50 days (28.00-346.00)]

   CA19-9 is a tumor marker that is used in the management of pancreatic cancer. Rising CA19-9 levels may mean the tumor is growing and decreasing CA19-9 levels may mean the tumor is shrinking or the amount of cancer in the body is decreasing A CA19-9 response means that the tumor marker has decreased over baseline (before treatment started) levels

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Histologically or cytologically proven metastatic or inoperable pancreatic adenocarcinoma.

• Measurable disease defined as lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as >10 mm with CT scan or MRI, as >20 mm by chest x-ray, or >10 mm with calipers by clinical exam.

• Must have progressed on, been intolerant to, or refused gemcitabine-based therapy.

• At least 18 years of age.

• ECOG performance status ≤ 2

• Normal bone marrow and organ function as defined below:

• Absolute neutrophil count ≥ 1,000/mcl

• Platelets ≥ 100,000/mcl

• Total bilirubin ≤ 2.0 mg/dL

• Creatinine ≤ 2.0 mg/dL

• AST or ALT ≤2.5 IULN (≤5X IULN if liver metastases are present)

• Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately.

• Able to understand and willing to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable).

Exclusion Criteria:

• Chemotherapy < 2 weeks prior to the first planned dose of study treatment.

• Radiotherapy < 3 weeks prior to the first planned dose of study treatment.

• A history of other malignancy ≤ 2 years previous with the exception of basal cell or squamous cell carcinoma of the skin which were treated with local resection only or carcinoma in situ of the cervix.

• Currently receiving any other investigational agents.

• Known brain metastases. Patients with known brain metastases must be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.

• A history of allergic reactions attributed to compounds of similar chemical or biologic composition to tosedostat or capecitabine or other agents used in the study.

• Previous treatment with any aminopeptidase inhibitor.

• Previous exposure to either 5-FU or capecitabine at a systemic dose except for use in concurrent chemoradiation.

• Known dihydropyrimidine dehydrogenase (DPD) deficiency or severe renal impairment (creatinine clearance < 30 mL/min by Cockcroft-Gault formula), as this would preclude use of capecitabine.

• Significant cardiovascular disease defined as:

• Myocardial infarction within 6 months of screening.

• Unstable angina pectoris

• Uncontrolled or clinically significant arrhythmia Grade ≥ 2

• LVEF ≤ below institutional limits at screening

• Congestive heart failure NYHA class III or IV

• Presence of clinically significant valvular heart disease

• Baseline troponin I or T > IULN and b-type natriuretic peptide > IULN.

• Prior exposure to cardiotoxic agent, such as anthracyclines, within 3 months of enrollment.

• Patient must have a QTc interval on ECG ≤ 0.48 seconds by Bazett's calculation at screening.

• Patient may not be taking any drugs that prolong the QT/QTc interval. If patient is on any of these drugs, patient may enroll in the study if the drugs can be discontinued for at least 5 half-lives prior to the first dose of tosedostat and capecitabine.

• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection or psychiatric illness/social situations that would limit compliance with study requirements.

• Pregnant and/or breastfeeding. Patients that are of childbearing age must have a negative pregnancy test at screening and agree on using contraception during the duration of the study.

• Known HIV-positivity on combination antiretroviral therapy because of the potential for pharmacokinetic interactions with tosedostat or capecitabine. In addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy. Appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Washington University School of Medicine	Saint Louis	Missouri	United States	63110

Sponsors and Collaborators

• Washington University School of Medicine

Investigators

• Principal Investigator: Andrea Wang-Gillam, M.D., Ph.D., Washington University School of Medicine

Study Documents (Full-Text)

• Study Protocol and Statistical Analysis Plan - Jul 11, 2017

More Information

Additional Information:

• Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

Publications

None provided.

• Responsible Party: Washington University School of Medicine
• ClinicalTrials.gov Identifier: NCT02352831
• Other Study ID Numbers: 201503074
• First Posted: Feb 2, 2015
• Last Update Posted: Aug 28, 2019
• Last Verified: Aug 1, 2019

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Additional relevant MeSH terms: Adenocarcinoma; Pancreatic Neoplasms; Capecitabine; Tosedostat

Study Results

Participant Flow

Recruitment Details	The study opened to participant enrollment on 08/31/2015 and closed to participant enrollment on 12/22/2017.

Arm/Group Title	Phase I (Tosedostat + Capecitabine)	Phase II (Tosedostat + Capecitabine)
Arm/Group Description	The phase I study will be conducted in the standard 6-patient-per-cohort dose de-escalation fashion. Tosedostat by mouth daily Days 1-21 of each 21-day cycle. Dose Level 0 (starting dose) = 120 mg PO daily and Dose Level -1 = 60 mg PO daily. All 6 patients in the Phase 1 received 120 mg starting dose of tosedostat. Capecitabine 1000 mg/m^2 by mouth BID Days 1-14 of each 21-day cycle Fresh tissue biopsy: Patients who have a partial response at the end of cycle 2 will be required to undergo biopsy if deemed safe for the patient and tissue is feasible to obtain.	Tosedostat (dose determined by Phase I portion of study) by mouth daily Days 1-21 of each 21-day cycle Capecitabine by mouth BID Days 1-14 of each 21-day cycle Fresh tissue biopsy: Patients who have a partial response at the end of cycle 2 will be required to undergo biopsy if deemed safe for the patient and tissue is feasible to obtain.
Period Title: Overall Study
STARTED	6	10
COMPLETED	6	10
NOT COMPLETED	0	0

Baseline Characteristics

Arm/Group Title	Phase I (Tosedostat + Capecitabine)	Phase II (Tosedostat + Capecitabine)	Total
Arm/Group Description	The phase I study will be conducted in the standard 6-patient-per-cohort dose de-escalation fashion. Tosedostat by mouth daily Days 1-21 of each 21-day cycle. Dose Level 0 (starting dose) = 120 mg PO daily and Dose Level -1 = 60 mg PO daily. All 6 patients in the Phase 1 received 120 mg starting dose of tosedostat. Capecitabine 1000 mg/m^2 by mouth BID Days 1-14 of each 21-day cycle Fresh tissue biopsy: Patients who have a partial response at the end of cycle 2 will be required to undergo biopsy if deemed safe for the patient and tissue is feasible to obtain.	Tosedostat (dose determined by Phase I portion of study) by mouth daily Days 1-21 of each 21-day cycle Capecitabine by mouth BID Days 1-14 of each 21-day cycle Fresh tissue biopsy: Patients who have a partial response at the end of cycle 2 will be required to undergo biopsy if deemed safe for the patient and tissue is feasible to obtain.	Total of all reporting groups
Overall Participants	6	10	16
Age (years) [Median (Full Range) ]
Median (Full Range) [years]	60.5	69.5	66
Sex: Female, Male (Count of Participants)
Female	3 50%	6 60%	9 56.3%
Male	3 50%	4 40%	7 43.8%
Ethnicity (NIH/OMB) (Count of Participants)
Hispanic or Latino	0 0%	0 0%	0 0%
Not Hispanic or Latino	6 100%	10 100%	16 100%
Unknown or Not Reported	0 0%	0 0%	0 0%
Race (NIH/OMB) (Count of Participants)
American Indian or Alaska Native	0 0%	0 0%	0 0%
Asian	0 0%	0 0%	0 0%
Native Hawaiian or Other Pacific Islander	0 0%	0 0%	0 0%
Black or African American	0 0%	1 10%	1 6.3%
White	6 100%	9 90%	15 93.8%
More than one race	0 0%	0 0%	0 0%
Unknown or Not Reported	0 0%	0 0%	0 0%
Region of Enrollment (participants) [Number]
United States	6 100%	10 100%	16 100%
Baseline CA19-9 (U/mL) [Mean (Full Range) ]
Mean (Full Range) [U/mL]	331.22	2061.73	1255

Outcome Measures

1. Primary Outcome

Title	Phase I Only: Recommended Phase II Dose of Tosedostat
Description	The recommended phase 2 dose (RP2D) is defined as the dose level immediately below the dose level at which 2 patients of a cohort (of 2 to 6 patients) experience dose-limiting toxicity during the first cycle. If 0 or 1 of 6 patients in Dose Level 1 experience DLT during the first cycle, Dose Level 1 will be presumed to be the RP2D. DLTs are followed through completion of the first cycle.
Time Frame	Completion of cycle 1 of all participants in Phase I portion of study (approximately 14 months)

Outcome Measure Data

Analysis Population Description

This outcome measure is for Phase I participants only.

Arm/Group Title	Phase I (Tosedostat + Capecitabine)	Phase II (Tosedostat + Capecitabine)
Arm/Group Description	The phase I study will be conducted in the standard 6-patient-per-cohort dose de-escalation fashion. Tosedostat by mouth daily Days 1-21 of each 21-day cycle. Dose Level 0 (starting dose) = 120 mg PO daily and Dose Level -1 = 60 mg PO daily. All 6 patients in the Phase 1 received 120 mg starting dose of tosedostat. Capecitabine 1000 mg/m^2 by mouth BID Days 1-14 of each 21-day cycle Fresh tissue biopsy: Patients who have a partial response at the end of cycle 2 will be required to undergo biopsy if deemed safe for the patient and tissue is feasible to obtain.	Tosedostat (dose determined by Phase I portion of study) by mouth daily Days 1-21 of each 21-day cycle Capecitabine by mouth BID Days 1-14 of each 21-day cycle Fresh tissue biopsy: Patients who have a partial response at the end of cycle 2 will be required to undergo biopsy if deemed safe for the patient and tissue is feasible to obtain.
Measure Participants	6	0
Number [mg daily]	120

2. Primary Outcome

Title	Phase I Only: Number of Participants Who Experience Dose-limiting Toxicities (DLTs)
Description	Possibly/probably/definitely related to study treatment in 1st cycle (cyc) *Grade (Gr) 4 neutropenia >7 day, Febrile neutropenia of any duration with temperature ≥ 38.5 °C, Gr 4 anemia requires transfusion therapy on more than 2 occasions in 7 days, Gr 4 thrombocytopenia Possibly/probably/definitely related gr. 3/4 non-hematologic toxicity that occurs 1st cyc with the following EXCEPTIONS: Gr 3 nausea/vomiting/diarrhea/anorexia <72 hours that returns to Gr 1 prior to the start of cyc 2, Gr 3 hand-foot syndrome will only be considered a DLT for patients who have received 1 week of supportive care treatment with no improvement, Gr 3 fatigue that returns to Gr 1 prior to the start of cyc 2, Gr 3 flu-like symptoms <72 hours that returns to Gr 1 prior to start of cyc 2, Gr 3 arthralgia or myalgias <72 hours that return to Gr 1 prior to the start of cyc 2, Gr 3 potassium/phosphorus/magnesium that is asymptomatic or of non-clinical significance <72 hours, Gr 3 hypoalbuminemia
Time Frame	Completion of cycle 1 of all participants in Phase I portion of study (approximately 14 months)

Outcome Measure Data

Analysis Population Description

This outcome measure is for Phase I participants only.

Arm/Group Title	Phase I (Tosedostat + Capecitabine)	Phase II (Tosedostat + Capecitabine)
Arm/Group Description	The phase I study will be conducted in the standard 6-patient-per-cohort dose de-escalation fashion. Tosedostat by mouth daily Days 1-21 of each 21-day cycle. Dose Level 0 (starting dose) = 120 mg PO daily and Dose Level -1 = 60 mg PO daily. All 6 patients in the Phase 1 received 120 mg starting dose of tosedostat. Capecitabine 1000 mg/m^2 by mouth BID Days 1-14 of each 21-day cycle Fresh tissue biopsy: Patients who have a partial response at the end of cycle 2 will be required to undergo biopsy if deemed safe for the patient and tissue is feasible to obtain.	Tosedostat (dose determined by Phase I portion of study) by mouth daily Days 1-21 of each 21-day cycle Capecitabine by mouth BID Days 1-14 of each 21-day cycle Fresh tissue biopsy: Patients who have a partial response at the end of cycle 2 will be required to undergo biopsy if deemed safe for the patient and tissue is feasible to obtain.
Measure Participants	6	0
Count of Participants [Participants]	1 16.7%

3. Primary Outcome

Title	Progression-free Survival (PFS) Rate
Description	PFS is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first. Progressive disease (PD) Target lesions: At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progressions). Non target lesions: Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase.
Time Frame	3 months

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Phase I (Tosedostat + Capecitabine)	Phase II (Tosedostat + Capecitabine)	Phase I and Phase II Combined
Arm/Group Description	The phase I study will be conducted in the standard 6-patient-per-cohort dose de-escalation fashion. Tosedostat by mouth daily Days 1-21 of each 21-day cycle. Dose Level 0 (starting dose) = 120 mg PO daily and Dose Level -1 = 60 mg PO daily. All 6 patients in the Phase 1 received 120 mg starting dose of tosedostat. Capecitabine 1000 mg/m^2 by mouth BID Days 1-14 of each 21-day cycle Fresh tissue biopsy: Patients who have a partial response at the end of cycle 2 will be required to undergo biopsy if deemed safe for the patient and tissue is feasible to obtain.	Tosedostat (dose determined by Phase I portion of study) by mouth daily Days 1-21 of each 21-day cycle Capecitabine by mouth BID Days 1-14 of each 21-day cycle Fresh tissue biopsy: Patients who have a partial response at the end of cycle 2 will be required to undergo biopsy if deemed safe for the patient and tissue is feasible to obtain.	Tosedostat by mouth daily Days 1-21 of each 21-day cycle Capecitabine by mouth BID Days 1-14 of each 21-day cycle Fresh tissue biopsy: Patients who have a partial response at the end of cycle 2 will be required to undergo biopsy if deemed safe for the patient and tissue is feasible to obtain.
Measure Participants	6	10	16
Count of Participants [Participants]	3 50%	8 80%	11 68.8%

4. Secondary Outcome

Title	Overall Response Rate (ORR)
Description	ORR = Complete response + partial response Target lesions Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Non target lesions *Complete Response (CR): Disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (<10 mm short axis).
Time Frame	Up to 18 months

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Phase I (Tosedostat + Capecitabine)	Phase II (Tosedostat + Capecitabine)
Arm/Group Description	The phase I study will be conducted in the standard 6-patient-per-cohort dose de-escalation fashion. Tosedostat by mouth daily Days 1-21 of each 21-day cycle. Dose Level 0 (starting dose) = 120 mg PO daily and Dose Level -1 = 60 mg PO daily. All 6 patients in the Phase 1 received 120 mg starting dose of tosedostat. Capecitabine 1000 mg/m^2 by mouth BID Days 1-14 of each 21-day cycle Fresh tissue biopsy: Patients who have a partial response at the end of cycle 2 will be required to undergo biopsy if deemed safe for the patient and tissue is feasible to obtain.	Tosedostat (dose determined by Phase I portion of study) by mouth daily Days 1-21 of each 21-day cycle Capecitabine by mouth BID Days 1-14 of each 21-day cycle Fresh tissue biopsy: Patients who have a partial response at the end of cycle 2 will be required to undergo biopsy if deemed safe for the patient and tissue is feasible to obtain.
Measure Participants	6	10
Count of Participants [Participants]	0 0%	0 0%

5. Secondary Outcome

Title	Time-to-progression (TTP)
Description	-Progressive disease (PD) Target lesions: At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progressions). Non target lesions: Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase
Time Frame	Up to 24 months

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Phase I (Tosedostat + Capecitabine)	Phase II (Tosedostat + Capecitabine)
Arm/Group Description	The phase I study will be conducted in the standard 6-patient-per-cohort dose de-escalation fashion. Tosedostat by mouth daily Days 1-21 of each 21-day cycle. Dose Level 0 (starting dose) = 120 mg PO daily and Dose Level -1 = 60 mg PO daily. All 6 patients in the Phase 1 received 120 mg starting dose of tosedostat. Capecitabine 1000 mg/m^2 by mouth BID Days 1-14 of each 21-day cycle Fresh tissue biopsy: Patients who have a partial response at the end of cycle 2 will be required to undergo biopsy if deemed safe for the patient and tissue is feasible to obtain.	Tosedostat (dose determined by Phase I portion of study) by mouth daily Days 1-21 of each 21-day cycle Capecitabine by mouth BID Days 1-14 of each 21-day cycle Fresh tissue biopsy: Patients who have a partial response at the end of cycle 2 will be required to undergo biopsy if deemed safe for the patient and tissue is feasible to obtain.
Measure Participants	6	10
Median (Full Range) [days]	210.50	94.50

6. Secondary Outcome

Title	Overall Survival Rate (OS)
Time Frame	Up to 1 year from completion of treatment (median treatment length 81.50 days (28.00-346.00)

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Phase I (Tosedostat + Capecitabine)	Phase II (Tosedostat + Capecitabine)	Phase I and Phase II (Tosedostat + Capecitabine)
Arm/Group Description	The phase I study will be conducted in the standard 6-patient-per-cohort dose de-escalation fashion. Tosedostat by mouth daily Days 1-21 of each 21-day cycle. Dose Level 0 (starting dose) = 120 mg PO daily and Dose Level -1 = 60 mg PO daily. All 6 patients in the Phase 1 received 120 mg starting dose of tosedostat. Capecitabine 1000 mg/m^2 by mouth BID Days 1-14 of each 21-day cycle Fresh tissue biopsy: Patients who have a partial response at the end of cycle 2 will be required to undergo biopsy if deemed safe for the patient and tissue is feasible to obtain.	Tosedostat (dose determined by Phase I portion of study) by mouth daily Days 1-21 of each 21-day cycle Capecitabine by mouth BID Days 1-14 of each 21-day cycle Fresh tissue biopsy: Patients who have a partial response at the end of cycle 2 will be required to undergo biopsy if deemed safe for the patient and tissue is feasible to obtain.	Tosedostat by mouth daily Days 1-21 of each 21-day cycle Capecitabine by mouth BID Days 1-14 of each 21-day cycle
Measure Participants	6	10	16
Count of Participants [Participants]	3 50%	2 20%	5 31.3%

7. Secondary Outcome

Title	Number of Participants With a CA19-9 Response
Description	CA19-9 is a tumor marker that is used in the management of pancreatic cancer. Rising CA19-9 levels may mean the tumor is growing and decreasing CA19-9 levels may mean the tumor is shrinking or the amount of cancer in the body is decreasing A CA19-9 response means that the tumor marker has decreased over baseline (before treatment started) levels
Time Frame	Completion of treatment (median treatment length 81.50 days (28.00-346.00)

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Phase I (Tosedostat + Capecitabine)	Phase II (Tosedostat + Capecitabine)
Arm/Group Description	The phase I study will be conducted in the standard 6-patient-per-cohort dose de-escalation fashion. Tosedostat by mouth daily Days 1-21 of each 21-day cycle. Dose Level 0 (starting dose) = 120 mg PO daily and Dose Level -1 = 60 mg PO daily. All 6 patients in the Phase 1 received 120 mg starting dose of tosedostat. Capecitabine 1000 mg/m^2 by mouth BID Days 1-14 of each 21-day cycle Fresh tissue biopsy: Patients who have a partial response at the end of cycle 2 will be required to undergo biopsy if deemed safe for the patient and tissue is feasible to obtain.	Tosedostat (dose determined by Phase I portion of study) by mouth daily Days 1-21 of each 21-day cycle Capecitabine by mouth BID Days 1-14 of each 21-day cycle Fresh tissue biopsy: Patients who have a partial response at the end of cycle 2 will be required to undergo biopsy if deemed safe for the patient and tissue is feasible to obtain.
Measure Participants	6	10
Count of Participants [Participants]	6 100%	10 100%

Adverse Events

Time Frame	Adverse events and all-cause mortality were collected from baseline through 30 days after treatment ended.
Arm/Group Title	Phase I (Tosedostat + Capecitabine)		Phase II (Tosedostat + Capecitabine)
Arm/Group Description	The phase I study will be conducted in the standard 6-patient-per-cohort dose de-escalation fashion. Tosedostat by mouth daily Days 1-21 of each 21-day cycle. Dose Level 0 (starting dose) = 120 mg PO daily and Dose Level -1 = 60 mg PO daily. All 6 patients in the Phase 1 received 120 mg starting dose of tosedostat. Capecitabine 1000 mg/m^2 by mouth BID Days 1-14 of each 21-day cycle Fresh tissue biopsy: Patients who have a partial response at the end of cycle 2 will be required to undergo biopsy if deemed safe for the patient and tissue is feasible to obtain.		Tosedostat (dose determined by Phase I portion of study) by mouth daily Days 1-21 of each 21-day cycle Capecitabine by mouth BID Days 1-14 of each 21-day cycle Fresh tissue biopsy: Patients who have a partial response at the end of cycle 2 will be required to undergo biopsy if deemed safe for the patient and tissue is feasible to obtain.
All Cause Mortality
	Phase I (Tosedostat + Capecitabine)		Phase II (Tosedostat + Capecitabine)
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	1/6 (16.7%)		1/10 (10%)
Serious Adverse Events
	Phase I (Tosedostat + Capecitabine)		Phase II (Tosedostat + Capecitabine)
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	3/6 (50%)		3/10 (30%)
Cardiac disorders
Acute coronary syndrome	1/6 (16.7%)		0/10 (0%)
Atrial fibrillation	0/6 (0%)		1/10 (10%)
Pericardial effusion	0/6 (0%)		1/10 (10%)
Gastrointestinal disorders
Colon obstruction	1/6 (16.7%)		0/10 (0%)
Gastric perforation	0/6 (0%)		1/10 (10%)
Infections and infestations
Pneumonia	0/6 (0%)		1/10 (10%)
Sepsis	1/6 (16.7%)		0/10 (0%)
Musculoskeletal and connective tissue disorders
Back pain	0/6 (0%)		1/10 (10%)
Vascular disorders
Superficial thrombephemelebitis	0/6 (0%)		1/10 (10%)
Other (Not Including Serious) Adverse Events
	Phase I (Tosedostat + Capecitabine)		Phase II (Tosedostat + Capecitabine)
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	6/6 (100%)		10/10 (100%)
Blood and lymphatic system disorders
Anemia	1/6 (16.7%)		2/10 (20%)
Eye disorders
Blurred vision	0/6 (0%)		2/10 (20%)
Dry eye	0/6 (0%)		1/10 (10%)
Gastrointestinal disorders
Abdominal pain	0/6 (0%)		3/10 (30%)
Constipation	1/6 (16.7%)		0/10 (0%)
Diarrhea	2/6 (33.3%)		5/10 (50%)
Dyspepsia	1/6 (16.7%)		3/10 (30%)
Dysphagia	1/6 (16.7%)		0/10 (0%)
Flatulence	1/6 (16.7%)		0/10 (0%)
Mucositis-oral	1/6 (16.7%)		1/10 (10%)
Nausea	2/6 (33.3%)		1/10 (10%)
Pancreatitis	0/6 (0%)		1/10 (10%)
Stomach pain	3/6 (50%)		0/10 (0%)
Vomiting	1/6 (16.7%)		0/10 (0%)
General disorders
Chills	1/6 (16.7%)		0/10 (0%)
Edema limbs	2/6 (33.3%)		3/10 (30%)
Fatigue	3/6 (50%)		1/10 (10%)
Fever	1/6 (16.7%)		1/10 (10%)
Pain	1/6 (16.7%)		0/10 (0%)
Sensation to cold	1/6 (16.7%)		0/10 (0%)
Infections and infestations
Nail infection	1/6 (16.7%)		0/10 (0%)
Toe infection	1/6 (16.7%)		0/10 (0%)
Investigations
Alkaline phosphatase	0/6 (0%)		4/10 (40%)
Blood bilirubin increased	0/6 (0%)		1/10 (10%)
Creatinine increase	0/6 (0%)		1/10 (10%)
Ejection fraction decreased	0/6 (0%)		4/10 (40%)
Hemoglobin decrease	6/6 (100%)		6/10 (60%)
Hypocalcemia	0/6 (0%)		2/10 (20%)
Increased amylase	0/6 (0%)		1/10 (10%)
Increased lipase	0/6 (0%)		1/10 (10%)
Lymphocytes decrease	2/6 (33.3%)		4/10 (40%)
Neutrophil count decrease	1/6 (16.7%)		0/10 (0%)
Platelet count decrease	6/6 (100%)		5/10 (50%)
White blood cells decrease	2/6 (33.3%)		3/10 (30%)
aPTT increase	0/6 (0%)		1/10 (10%)
Metabolism and nutrition disorders
ALT increase	3/6 (50%)		3/10 (30%)
AST increase	3/6 (50%)		3/10 (30%)
Anorexia	3/6 (50%)		0/10 (0%)
Hypercalcemia	1/6 (16.7%)		0/10 (0%)
Hyperglycemia	0/6 (0%)		3/10 (30%)
Hyperkalemia	1/6 (16.7%)		0/10 (0%)
Hypoalbuminemia	2/6 (33.3%)		4/10 (40%)
Musculoskeletal and connective tissue disorders
Back pain	1/6 (16.7%)		3/10 (30%)
Muscle weakness	1/6 (16.7%)		0/10 (0%)
Nervous system disorders
Dizziness	1/6 (16.7%)		2/10 (20%)
Tingling of lips	0/6 (0%)		1/10 (10%)
Psychiatric disorders
Anxiety	2/6 (33.3%)		1/10 (10%)
Depression	0/6 (0%)		1/10 (10%)
Insomnia	2/6 (33.3%)		0/10 (0%)
Respiratory, thoracic and mediastinal disorders
Cough	1/6 (16.7%)		1/10 (10%)
Dyspnea	3/6 (50%)		1/10 (10%)
Skin and subcutaneous tissue disorders
Dry skin	1/6 (16.7%)		0/10 (0%)
Nail ridging	0/6 (0%)		1/10 (10%)
Palmar-plantar	1/6 (16.7%)		1/10 (10%)
Rash maculo-papular	2/6 (33.3%)		0/10 (0%)
Vascular disorders
Hypertension	2/6 (33.3%)		1/10 (10%)

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

All Principal Investigators ARE employed by the organization sponsoring the study.

There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.